Portal de investigación
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Garderet, L
- Ziagkos, D
- Van Biezen, A
- Iacobelli S
- Finke, J
- Maertens, J
- Volin, L
- Ljungman, P
- Chevallier, P
- Passweg, J
- Schaap, N
- Beelen, D
- Nagler, A
- Blaise, D
- Poire, X
- Yakoub-Agha, I
- Lenhoff, S
- Craddock, C
- Schots, R
- Rambaldi, A
- Jindra, P
- Mufti, GJ
- Robin, M
- Kröger N
Grupos
Abstract
The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [al]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P <.001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality. (C) 2017 American Society for Blood and Marrow Transplantation.
Datos de la publicación
- ISSN/ISSNe:
- 1083-8791, 1523-6536
- Tipo:
- Article
- Páginas:
- 507-513
- PubMed:
- 29196078
- Factor de Impacto:
- 2,087 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 12
Documentos
- No hay documentos
Filiaciones
Keywords
- MDS; del (5q); Allogeneic stem cell transplantation
Cita
Garderet L,Ziagkos D,Van A,Iacobelli S,Finke J,Maertens J,Volin L,Ljungman P,Chevallier P,Passweg J,Schaap N,Beelen D,Nagler A,Blaise D,Poire X,Yakoub I,Lenhoff S,Craddock C,Schots R,Rambaldi A,SANZ J,Jindra P,Mufti GJ,Robin M,Kröger N. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. Biol. Blood Marrow Transplant. 2018. 24. (3):p. 507-513. IF:3,599. (2).